0001157523-23-000728.txt : 20230504 0001157523-23-000728.hdr.sgml : 20230504 20230504081025 ACCESSION NUMBER: 0001157523-23-000728 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230504 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230504 DATE AS OF CHANGE: 20230504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 23886645 BUSINESS ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 8-K 1 a53393280.htm ALNYLAM PHARMACEUTICALS, INC. 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  May 4, 2023
 
Alnylam Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)


Delaware
001-36407
77-0602661
(State or Other Juris-
diction of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)


675 West Kendall Street,
Henri A. Termeer Square
Cambridge, Massachusetts
02142
(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number, including area code:  (617) 551-8200
 
Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class
   Trading Symbol(s)
  
Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share
   ALNY
   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company     ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐


Item 2.02.         Results of Operations and Financial Condition
 
On May 4, 2023, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


Item 9.01.         Financial Statements and Exhibits

     (d)     Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:


104
Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURE

          Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 4, 2023
ALNYLAM PHARMACEUTICALS, INC.
     
     
 
By:
/s/    Jeffrey V. Poulton
   
Jeffrey V. Poulton
   
Executive Vice President, Chief Financial Officer


EX-99.1 2 a53393280ex99_1.htm EXHIBIT 99.1
Exhibit 99.1

Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

− Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 –

− Reported Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy, Establishing First-Ever Human Translation of RNAi Therapeutics in CNS –

− Reiterated 2023 Financial Guidance, Including Combined Net Product Revenues of $1,200 Million to $1,285 Million –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.

“The first quarter of 2023 saw continued strong commercial execution, driven by the ongoing launch of AMVUTTRA, delivering robust 48% growth in total product sales compared with the first quarter 2022. We also made significant progress with our broad pipeline, delivering positive first-in-human results for an RNAi therapeutic in the CNS from an interim analysis of the Phase 1 study of ALN-APP in patients with early-onset Alzheimer’s disease. We believe this proof of concept is a significant catalyst for future potential growth for Alnylam with the expansion of our product engine to include tissues beyond the liver,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “We’re also excited for other key upcoming milestones from our pipeline, including topline Phase 2 results from the KARDIA-1 study of zilebesiran, which are expected mid-year. With this continued execution, we believe we are tracking well toward our Alnylam P5x25 goals of becoming a top-tier biotech company delivering sustained innovation and exceptional financial results.”

First Quarter 2023 and Recent Significant Corporate Highlights

Commercial Performance

Total TTR: ONPATTRO® (patisiran) & AMVUTTRA® (vutrisiran)

  • Achieved global net product revenues for ONPATTRO and AMVUTTRA for the first quarter of $102 million and $102 million, respectively, representing 49% total TTR reported year-over-year growth compared to Q1 2022 and 54% growth on a CER* basis.
  • Attained over 3,160 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with ONPATTRO or AMVUTTRA as of March 31, 2023.

Total Ultra-Rare: GIVLAARI® (givosiran) & OXLUMO® (lumasiran)

  • Achieved global net product revenues for GIVLAARI and OXLUMO for the first quarter of $48 million and $24 million, respectively, representing 45% total Ultra-Rare reported year-over-year growth compared to Q1 2022 and 48% on a CER* basis.
  • Attained over 550 patients worldwide on commercial GIVLAARI treatment as of March 31, 2023.
  • Attained over 300 patients worldwide on commercial OXLUMO treatment as of March 31, 2023.

Leqvio® (inclisiran)

  • Launch in the U.S. and other markets is ongoing, with focus on patient on-boarding, removing access hurdles and enhancing medical education. In the U.S. Leqvio is covered at or near label for 76% of patients 14 months after launch. More than 50% of Leqvio source of business in the U.S. is now through “Buy and Bill” acquisition model.

R&D Highlights

Reported positive interim results from the ongoing single ascending dose (SAD) part of the Phase 1 study of ALN-APP in patients with early-onset Alzheimer’s disease (EOAD). These results establish the first human translation of Alnylam’s proprietary C16-siRNA conjugate platform for central nervous system (CNS) delivery and are the first clinical demonstration of gene silencing in the human brain using an RNAi therapeutic.

The Company announces today that it has submitted 18-month data from the APOLLO-B Phase 3 study to the U.S. FDA as part of the sNDA review for ONPATTRO (patisiran) for the treatment of the cardiomyopathy of ATTR amyloidosis.

Sanofi announced that results from the ATLAS-INH and ATLAS-A/B studies evaluating the efficacy and safety of fitusiran were published respectively in The Lancet and The Lancet Haematology, reinforcing the potential of investigational fitusiran to transform the current standard of care and address unmet needs for all types of hemophilia, regardless of inhibitor status.

Additional Key Pipeline Progress:

  • Submitted an sNDA to the Brazilian Health Regulatory Agency (ANVISA) for ONPATTRO (patisiran) for the treatment of the cardiomyopathy of ATTR amyloidosis.
  • Presented post-hoc analyses from the Phase 3 ENVISION study of givosiran in patients with AHP through Month 36 at the Hemostasis & Thrombosis Research Society (HTRS) Scientific Symposium.
  • Presented preclinical data for ALN-HTT, for the potential treatment of Huntington’s disease, at the CHDI 18th Annual Huntington’s Disease Therapeutics Conference, in collaboration with Regeneron.
  • Announced today that dosing has been initiated in a Phase 1 study of ALN-KHK, for the potential treatment of type 2 diabetes.
  • Regeneron announced that it has initiated a Phase 2 study of ALN-HSD in patients with NASH.
  • Vir initiated the Phase 2 PREVAIL platform trial and its THRIVE/STRIVE sub-protocols evaluating combinations of ALN-HBV02 (VIR-2218) and VIR-3434 and/or PEG-IFN-α in two hepatitis B virus (HBV) patient populations, with the potential to evaluate other populations in the future. Initial data are expected in the first half of 2024.

Additional Business Updates

  • Appointed Peter Kellogg to its Board of Directors.
  • Published 2022 Corporate Responsibility Report.
  • Named Fast Company Top Workplace for Innovators.
  • Ranked #6 for gender diversity among executive leadership and #1 for gender diversity among board of directors in the Eos Foundation’s Women’s Power Gap study.

Upcoming Events

Alnylam announces today that it intends to present 18-month results from the APOLLO-B Phase 3 study of patisiran at ESC-HF 2023, being held May 20-23, 2023 in Prague.

Alnylam also announces today that it intends to present results from the Randomized Treatment Extension (RTE) of the HELIOS-A Phase 3 study evaluating a biannual dosing regimen of vutrisiran at the Italian Association for the Study of the Peripheral Nervous System (ASNP) conference, being held May 25-27, 2023 in Naples.

In addition, in early and mid-2023:

  • Alnylam intends to report topline results from the KARDIA-1 Phase 2 study of zilebesiran.
    • Alnylam also intends to complete enrollment in the KARDIA-2 Phase 2 study of zilebesiran.
  • Vir is conducting multiple trials evaluating the potential for ALN-HBV02 (VIR-2218) and VIR-3434 to achieve a functional cure for chronic HBV, which remain ongoing with readouts expected in 2023.
    • Vir also announced that the Phase 2 SOLSTICE trial evaluating ALN-HBV02 (VIR-2218) and VIR-232 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus, the most aggressive form of viral hepatitis, remains ongoing with data expected in the second half of 2023.

Financial Results for the Quarter Ended March 31, 2023

 

Three Months Ended
March 31,

(in thousands, except per share amounts)

 

2023

 

 

 

2022

 

Net product revenues

$

276,328

 

 

$

186,872

 

Net revenue from collaborations

$

36,462

 

 

$

25,945

 

Royalty revenue

$

6,500

 

 

$

442

 

 

 

 

 

GAAP Operating loss

$

(149,807

)

 

$

(146,732

)

Non-GAAP Operating loss

$

(109,860

)

 

$

(117,439

)

 

 

 

 

GAAP Net loss

$

(174,101

)

 

$

(240,341

)

Non-GAAP Net loss

$

(131,887

)

 

$

(179,887

)

 

 

 

 

GAAP Net loss per common share – basic and diluted

$

(1.40

)

 

$

(2.00

)

Non-GAAP Net loss per common share – basic and diluted

$

(1.06

)

 

$

(1.49

)

Net Product Revenues

 

Three Months Ended
March 31,

 

Year over Year %
Growth

(in thousands, except percentages)

2023

 

2022

 

As Reported

 

At CER*

ONPATTRO net product revenues

$

102,493

 

$

137,009

 

(25

)%

 

(23

)%

AMVUTTRA net product revenues

 

101,768

 

----

 

N/A

 

 

N/A

 

Total TTR net product revenues

$

204,261

 

$

137,009

 

49

%

 

54

%

 

 

 

 

 

 

 

 

GIVLAARI net product revenues

 

47,906

 

 

35,277

 

36

%

 

39

%

OXLUMO net product revenues

 

24,161

 

 

14,586

 

66

%

 

70

%

Total net product revenues

$

276,328

 

$

186,872

 

48

%

 

52

%












 

* CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the first quarter 2022. CER is a Non-GAAP measure.

  • Net product revenues increased 48% at actual currency during the first quarter 2023, as compared to the prior year, and 52% at CER. The increase is primarily related to growth in our TTR product revenues driven by the launch of AMVUTTRA in the U.S. in the third quarter of 2022 as well as increased patients on GIVLAARI and OXLUMO therapies.

Net Revenues from Collaborations

  • Net revenues from collaborations increased 41% during the first quarter 2023, as compared to the prior year, primarily due to an increase in revenue from our collaboration arrangements with Regeneron attributed to an increase in reimbursable activities under our research services arrangement in addition to an increase in revenue recognized associated with licensed programs within the collaboration.

Operating Expenses

 

Three Months Ended
March 31,

 

2023 vs. 2022

(in thousands, except percentages)

 

2023

 

 

 

2022

 

 

% Change*

Cost of goods sold

$

41,432

 

 

$

23,457

 

 

77

%

Cost of goods sold as a percentage of net product revenues

 

15.0

%

 

 

12.6

%

 

2.4

%

 

 

 

 

 

 

Cost of collaborations

$

13,437

 

 

$

12,170

 

 

10

%

 

 

 

 

 

 

GAAP research and development expenses

$

230,569

 

 

$

169,893

 

 

36

%

Non-GAAP research and development expenses

$

214,337

 

 

$

158,276

 

 

35

%

 

 

 

 

 

 

GAAP selling, general and administrative expenses

$

183,659

 

 

$

154,471

 

 

19

%

Non-GAAP selling, general and administrative expenses

$

159,944

 

 

$

136,795

 

 

17

%

* For dollar values, we calculate the percentage of change during Q1 2023 compared to Q1 2022. For cost of goods sold as a percentage of net product revenues, we calculate the basis point change during Q1 2023 compared to Q1 2022.

Cost of Goods Sold

  • Cost of goods sold as a percent of product sales increased during the first quarter 2023, as compared to the prior year, primarily due to increased royalties due to third parties driven by sales of AMVUTTRA partially offset by lower manufacturing costs for AMVUTTRA compared with ONPATTRO.

Research & Development (R&D) Expenses

  • GAAP and non-GAAP R&D expenses increased during the first quarter 2023, as compared to the prior year, primarily due to increases in headcount to support our R&D pipeline, development expenses associated with the APOLLO-B (patisiran), HELIOS-B (vutrisiran), and KARDIA-1/KARDIA-2 (zilebesiran) clinical studies, and manufacturing related expenses associated with our pre-clinical activities.

Selling, General & Administrative (SG&A) Expenses

  • GAAP and non-GAAP SG&A expenses increased during the first quarter 2023, as compared to the prior year, primarily due to increased headcount and other investments supporting our strategic growth, including the global launch of AMVUTTRA.

Other Financial Highlights

  • Cash, cash equivalents and marketable securities were $2.07 billion as of March 31, 2023 compared to $2.19 billion as of December 31, 2022 with the decrease primarily due to our operating loss in the first quarter 2023.

The adjustments to the non-GAAP measures provided in the financial results above and in the financial guidance below are described under “Use of Non-GAAP Financial Measures” later in this press release. A reconciliation of our GAAP to non-GAAP results presented in this release is included in the tables at the end of this press release.

2023 Financial Guidance1

Full year 2023 financial guidance is reiterated and consists of the following:

Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1,2

$1,200 million – $1,285 million

Net Product Revenue Growth vs. 2022 at reported Fx rates1

34% to 44%

Net Product Revenue Growth vs. 2022 at constant exchange rates*

34% to 44%

Net revenues from collaborations and royalties

$100 million – $175 million

GAAP R&D and SG&A expenses

$1,790 million – $1,885 million

Non-GAAP R&D and SG&A expenses3

$1,575 million – $1,650 million

1 Uses December 31, 2022 Fx rates including: 1 EUR = 1.07 USD and 1 USD = 131 JPY

2 Assumes U.S. sNDA approval of patisiran for ATTR amyloidosis with cardiomyopathy by the PDUFA date on October 8, 2023

3 Excludes $215-$235 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses

* CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the twelve months ended December 31, 2022. CER is a Non-GAAP measure.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, including expenses adjusted to exclude certain non-cash expenses and certain losses outside the ordinary course of the Company’s business. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies.

The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are stock-based compensation expenses and realized and unrealized losses on marketable equity securities. The Company has excluded the impact of stock-based compensation expense, which may fluctuate from period to period based on factors including the variability associated with performance-based grants for stock options and restricted stock units and changes in the Company’s stock price, which impacts the fair value of these awards. The Company has excluded the impact of the realized and unrealized losses on marketable equity securities because the Company does not believe these adjustments accurately reflect the performance of the Company’s ongoing operations for the period in which such gains or losses are reported, as their sole purpose is to adjust amounts on the balance sheet.

Percentage changes in revenue growth at CER, also a non-GAAP financial measure, are presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. The current period’s foreign currency revenue values are converted into U.S. dollars using the average exchange rates from the prior period.

The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance and are better able to compare the Company’s performance between periods. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between historical GAAP and non-GAAP measures presented in this release is provided later in this press release.

Conference Call Information

Management will provide an update on the Company and discuss first quarter 2023 results as well as expectations for the future via conference call on Thursday, May 4, 2023 at 8:30 am ET. To access the call, please register online at https://register.vevent.com/register/BId2c9a28af23d4f119b97d77675d085dc. Participants are requested to register at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months.

A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.

About ONPATTRO® (patisiran)

ONPATTRO is an RNAi therapeutic that is approved in the United States and Canada for the treatment of the polyneuropathy of hATTR amyloidosis in adults. ONPATTRO is also approved in the European Union, Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy, and in Japan for the treatment of hATTR amyloidosis with polyneuropathy. ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and silence TTR messenger RNA, thereby reducing the production of TTR protein before it is made. Reducing the pathogenic protein leads to a reduction in amyloid deposits in tissues. For more information about ONPATTRO, including full Prescribing Information, visit ONPATTRO.com.

About AMVUTTRA® (vutrisiran)

AMVUTTRA® (vutrisiran) is an RNAi therapeutic approved in the United States for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is a double‑stranded small interfering RNA (siRNA) that targets mutant and wild‑type transthyretin (TTR) messenger RNA (mRNA). Using Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery platform, AMVUTTRA is designed for increased potency and high metabolic stability to allow for subcutaneous injection once every three months (quarterly). Results from the pivotal HELIOS-A Phase 3 study demonstrate AMVUTTRA rapidly reduces serum TTR levels, has the potential to reverse neuropathy impairment relative to baseline and improves other key measures of disease burden relative to external placebo in patients with the polyneuropathy of hATTR amyloidosis. For more information about AMVUTTRA, including the full U.S. Prescribing Information, visit AMVUTTRA.com.

About GIVLAARI® (givosiran)

GIVLAARI (givosiran) is an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) approved in the United States and Brazil for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is also approved in the European Union for the treatment of AHP in adults and adolescents aged 12 years and older. In the pivotal study, givosiran was shown to significantly reduce the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or intravenous hemin administration at home compared to placebo. GIVLAARI is Alnylam’s first commercially available therapeutic based on its Enhanced Stabilization Chemistry ESC-GalNAc conjugate technology to increase potency and durability. GIVLAARI is administered via subcutaneous injection once monthly at a dose based on actual body weight and should be administered by a healthcare professional. GIVLAARI works by specifically reducing elevated levels of ALAS1 messenger RNA (mRNA), leading to reduction of toxins associated with attacks and other disease manifestations of AHP. For more information about GIVLAARI, including the full U.S. Prescribing Information, visit GIVLAARI.com.

About OXLUMO® (lumasiran)

OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1). HAO1 encodes glycolate oxidase (GO). Thus, by silencing HAO1 and depleting the GO enzyme, OXLUMO inhibits production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1. OXLUMO utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. OXLUMO has received regulatory approvals from the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients and from the European Medicines Agency (EMA) for the treatment of PH1 in all age groups. In the pivotal ILLUMINATE-A study, OXLUMO was shown to significantly reduce levels of urinary oxalate relative to placebo, with the majority of patients reaching normal or near-normal levels. In the ILLUMINATE-B pediatric Phase 3 study, OXLUMO demonstrated an efficacy and safety profile consistent to that observed in ILLUMINATE-A. In the ILLUMINATE-C study, OXLUMO resulted in substantial reductions in plasma oxalate in patients with advanced PH1. Across all three studies, injection site reactions (ISRs) were the most common drug-related adverse reaction. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly beginning one month after the last loading dose at a dose based on actual body weight. For patients who weigh less than 10 kg, ongoing dosing remains monthly. OXLUMO should be administered by a healthcare professional. For more information about OXLUMO, including the full U.S. Prescribing Information, visit OXLUMO.com.

About LNP Technology

Alnylam has licenses to Arbutus Biopharma LNP intellectual property for use in RNAi therapeutic products using LNP technology.

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

Alnylam Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, expectations regarding Alnylam’s aspiration to become a leading biotech company and the planned achievement of its “Alnylam P5x25” strategy, the potential for Alnylam to identify new potential drug development candidates and advance its research and development programs, Alnylam’s ability to obtain approval for new commercial products or additional indications for its existing products, and Alnylam’s projected commercial and financial performance, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition; Alnylam’s ability to successfully execute on its “Alnylam P5x25” strategy; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates, including patisiran and vutrisiran; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, including patisiran and vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam’s approved products globally; delays, interruptions or failures in the manufacture and supply of Alnylam’s product candidates or its marketed products; delays or interruptions in the supply of resources needed to advance Alnylam’s research and development programs, including as may arise from the recent disruptions in the supply of non-human primates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to successfully expand the indication for ONPATTRO or AMVUTTRA in the future; Alnylam's ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam's dependence on third parties for the development and commercialization of certain products, including Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the potential impact of a current government investigation and the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam's 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

This release discusses investigational RNAi therapeutics and uses of previously approved RNAi therapeutics in development and is not intended to convey conclusions about efficacy or safety as to those investigational therapeutics or uses. Patisiran has not been approved by any regulatory agency for the treatment of ATTR amyloidosis with cardiomyopathy. No conclusions can or should be drawn regarding its safety or effectiveness in treating cardiomyopathy in this population. There is no guarantee that any investigational therapeutics or expanded uses of commercial products will successfully complete clinical development or gain health authority approval.

ALNYLAM PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)



 

 

Three Months Ended

 

 

March 31,
2023

 

March 31,
2022

 

Statements of Operations

 

 

 

 

Revenues:

 

 

 

 

Net product revenues

$

276,328

 

 

$

186,872

 

 

Net revenues from collaborations

 

36,462

 

 

 

25,945

 

 

Royalty revenue

 

6,500

 

 

 

442

 

 

Total revenues

 

319,290

 

 

 

213,259

 

 

 

 

 

 

 

Operating costs and expenses:

 

 

 

 

Cost of goods sold

 

41,432

 

 

 

23,457

 

 

Cost of collaborations and royalties

 

13,437

 

 

 

12,170

 

 

Research and development

 

230,569

 

 

 

169,893

 

 

Selling, general and administrative

 

183,659

 

 

 

154,471

 

 

Total operating costs and expenses

 

469,097

 

 

 

359,991

 

 

Loss from operations

 

(149,807

)

 

 

(146,732

)

 

Other (expense) income:

 

 

 

 

Interest expense

 

(28,955

)

 

 

(42,362

)

 

Interest income

 

18,655

 

 

 

1,012

 

 

Other expense, net

 

(12,255

)

 

 

(51,274

)

 

Total other expense, net

 

(22,555

)

 

 

(92,624

)

 

Loss before income taxes

 

(172,362

)

 

 

(239,356

)

 

Provision for income taxes

 

(1,739

)

 

 

(985

)

 

Net loss

$

(174,101

)

 

$

(240,341

)

 

Net loss per common share - basic and diluted

$

(1.40

)

 

$

(2.00

)

 

Weighted-average common shares used to compute basic and diluted net loss per common share

 

124,111

 

 

 

120,393

 

 


ALNYLAM PHARMACEUTICALS, INC.

RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES

(In thousands, except per share amounts)

(Unaudited)



 

 

Three Months Ended

 

 

March 31,
2023

 

March 31, 2022

 

Reconciliation of GAAP to Non-GAAP research and development:

 

 

 

 

GAAP research and development

$

230,569

 

 

$

169,893

 

 

Less: Stock-based compensation expenses

 

(16,232

)

 

 

(11,617

)

 

Non-GAAP research and development

$

214,337

 

 

$

158,276

 

 

 

 

 

 

 

Reconciliation of GAAP to Non-GAAP selling, general and administrative:

 

 

 

 

GAAP selling, general and administrative

$

183,659

 

 

$

154,471

 

 

Less: Stock-based compensation expenses

 

(23,715

)

 

 

(17,676

)

 

Non-GAAP selling, general and administrative

$

159,944

 

 

$

136,795

 

 

 

 

 

 

 

Reconciliation of GAAP to Non-GAAP operating loss:

 

 

 

 

GAAP operating loss

$

(149,807

)

 

$

(146,732

)

 

Add: Stock-based compensation expenses

 

39,947

 

 

 

29,293

 

 

Non-GAAP operating loss

$

(109,860

)

 

$

(117,439

)

 

 

 

 

 

 

Reconciliation of GAAP to Non-GAAP net loss:

 

 

 

 

GAAP net loss

$

(174,101

)

 

$

(240,341

)

 

Add: Stock-based compensation expenses

 

39,947

 

 

 

29,293

 

 

Add: Realized and unrealized loss on marketable equity securities

 

2,267

 

 

 

31,161

 

 

Non-GAAP net loss

$

(131,887

)

 

$

(179,887

)

 

 

 

 

 

 

Reconciliation of GAAP to Non-GAAP net loss per common share-basic and diluted:

 

 

 

 

GAAP net loss per common share - basic and diluted

$

(1.40

)

 

$

(2.00

)

 

Add: Stock-based compensation expenses

 

0.32

 

 

 

0.24

 

 

Add: Realized and unrealized loss on marketable equity securities

 

0.02

 

 

 

0.26

 

 

Non-GAAP net loss per common share - basic and diluted

$

(1.06

)

 

$

(1.49

)

 









 

Please note that the figures presented above may not sum exactly due to rounding


ALNYLAM PHARMACEUTICALS, INC.

RECONCILIATION OF GAAP TO NON-GAAP

PRODUCT REVENUE GROWTH AT CONSTANT CURRENCY

(Unaudited)


 

 

Three Months Ended March 31, 2023

ONPATTRO net product revenue growth, as reported

(25

)%

Add: Impact of foreign currency translation

2

 

ONPATTRO net product revenue growth at constant currency

(23

)%

 

 

AMVUTTRA net product revenue growth, as reported

N/A

 

Add: Impact of foreign currency translation

N/A

 

AMVUTTRA net product revenue growth at constant currency

—

%

 

 

Total TTR net product revenue growth, as reported

49

%

Add: Impact of foreign currency translation

5

 

Total TTR net product revenue growth at constant currency

54

%

 

 

GIVLAARI net product revenue growth, as reported

36

%

Add: Impact of foreign currency translation

3

 

GIVLAARI net product revenue growth at constant currency

39

%

 

 

OXLUMO net product revenue growth, as reported

66

%

Add: Impact of foreign currency translation

4

 

OXLUMO net product revenue growth at constant currency

70

%

 

 

Total Ultra Rare net product revenue growth, as reported

45

%

Add: Impact of foreign currency translation

3

 

Total Ultra Rare net product revenue growth at constant currency

48

%

 

 

Total net product revenue growth, as reported

48

%

Add: Impact of foreign currency translation

4

 

Total net product revenue growth at constant currency

52

%


ALNYLAM PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited)




 

 

March 31, 2023

 

December 31, 2022

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

672,245

 

 

$

866,394

 

Marketable debt securities

 

1,372,574

 

 

 

1,297,890

 

Marketable equity securities

 

25,856

 

 

 

28,122

 

Accounts receivable, net

 

219,434

 

 

 

237,963

 

Inventory

 

131,879

 

 

 

128,962

 

Prepaid expenses and other current assets

 

119,030

 

 

 

132,916

 

Total current assets

 

2,541,018

 

 

 

2,692,247

 

Property, plant and equipment, net

 

523,032

 

 

 

523,494

 

Operating lease right-of-use assets

 

215,049

 

 

 

215,136

 

Restricted investments

 

49,388

 

 

 

49,390

 

Other assets

 

63,453

 

 

 

66,092

 

Total assets

$

3,391,940

 

 

$

3,546,359

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

62,237

 

 

$

98,094

 

Accrued expenses

 

508,599

 

 

 

545,460

 

Operating lease liability

 

43,055

 

 

 

41,967

 

Deferred revenue

 

35,794

 

 

 

42,105

 

Liability related to the sale of future royalties

 

23,706

 

 

 

40,289

 

Total current liabilities

 

673,391

 

 

 

767,915

 

Operating lease liability, net of current portion

 

259,399

 

 

 

261,339

 

Deferred revenue, net of current portion

 

191,257

 

 

 

193,791

 

Convertible debt

 

1,017,887

 

 

 

1,016,942

 

Liability related to the sale of future royalties, net of current portion

 

1,285,200

 

 

 

1,252,015

 

Other liabilities

 

224,046

 

 

 

212,580

 

Total liabilities

 

3,651,180

 

 

 

3,704,582

 

Commitments and contingencies (Note 13)

 

 

 

Stockholders’ deficit:

 

 

 

Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March 31, 2023 and December 31, 2022

 

—

 

 

 

—

 

Common stock, $0.01 par value per share, 250,000 shares authorized; 124,241 shares issued and outstanding as of March 31, 2023; 123,925 shares issued and outstanding as of December 31, 2022

 

1,243

 

 

 

1,240

 

Additional paid-in capital

 

6,522,091

 

 

 

6,454,540

 

Accumulated other comprehensive loss

 

(39,124

)

 

 

(44,654

)

Accumulated deficit

 

(6,743,450

)

 

 

(6,569,349

)

Total stockholders’ deficit

 

(259,240

)

 

 

(158,223

)

Total liabilities and stockholders’ deficit

$

3,391,940

 

 

$

3,546,359

 

This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alnylam’s Annual Report on Form 10-K which includes the audited financial statements for the year ended December 31, 2022.

 

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340

Josh Brodsky
(Investors)
617-551-8276

EX-101.SCH 3 alny-20230504.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 alny-20230504_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 alny-20230504_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 04, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 04, 2023
Entity Registrant Name Alnylam Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36407
Entity Tax Identification Number 77-0602661
Entity Address, Address Line One 675 West Kendall Street
Entity Address, Address Line Two Henri A. Termeer Square
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 551-8200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001178670
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol ALNY
Security Exchange Name NASDAQ
XML 7 a53393280_htm.xml IDEA: XBRL DOCUMENT 0001178670 2023-05-04 2023-05-04 false 0001178670 8-K 2023-05-04 Alnylam Pharmaceuticals, Inc. DE 001-36407 77-0602661 675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142 617 551-8200 false false false false Common Stock, $0.01 par value per share ALNY NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://alnylam.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a53393280.htm a53393280ex99_1.htm alny-20230504.xsd alny-20230504_lab.xml alny-20230504_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a53393280.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "a53393280.htm" ] }, "labelLink": { "local": [ "alny-20230504_lab.xml" ] }, "presentationLink": { "local": [ "alny-20230504_pre.xml" ] }, "schema": { "local": [ "alny-20230504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alny", "nsuri": "http://alnylam.com/20230504", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a53393280.htm", "contextRef": "c20230504to20230504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://alnylam.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a53393280.htm", "contextRef": "c20230504to20230504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alnylam.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001157523-23-000728-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-23-000728-xbrl.zip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�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

2TR,#(S,#4P-%]P <&UL4$L%!@ % 4 00$ !UY $! end